Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA for Plantar Fasciitis
NCT03825315Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daxibotulinumtoxinA in plantar fasciitis (3 arms), sponsored by Revance Therapeutics. Primary endpoint: Numeric Pain Rating Scale at 8 weeks. Started Dec 2018; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
plantar fasciitis
Beyond the preview
Go deeper on NCT03825315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825315.